ExpreS2ion Biotech Holding AB Cash Flow Conversion Efficiency
ExpreS2ion Biotech Holding AB cash flow conversion efficiency. Based on the latest financial reports, ExpreS2ion Biotech Holding AB (EXPRS2) has a cash flow conversion efficiency ratio of -0.965x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-25.49 Million ≈ $-2.74 Million USD) by net assets (Skr26.42 Million ≈ $2.84 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of ExpreS2ion Biotech Holding AB (2016–2025)
Cash flow conversion efficiency of ExpreS2ion Biotech Holding AB from 2016 to 2025. This chart illustrates how ExpreS2ion Biotech Holding AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View EXPRS2 stock price and chart for real-time trading data and today's change.
ExpreS2ion Biotech Holding AB Cash Flow Conversion Ratio Explained
ExpreS2ion Biotech Holding AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
ExpreS2ion Biotech Holding AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ExpreS2ion Biotech Holding AB ranked by their cash flow conversion efficiency. Also see EXPRS2 company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Critical Metals Plc
LSE:CRTM
|
-0.534x |
|
Story-I Ltd
AU:SRY
|
3.211x |
|
Agrogalaxy Participacoes SA
SA:AGXY3
|
-0.339x |
|
TV Vision Limited
NSE:TVVISION
|
-0.013x |
|
Grupo Famsa S.A.B. de C.V
MX:GFAMSAA
|
0.002x |
|
Octopus Aim Vct Plc
LSE:OOA
|
-0.006x |
|
Robert Walters
LSE:RWA
|
0.002x |
|
Asian Television Network International Ltd
V:SAT
|
-0.121x |
Annual Cash Flow Conversion Efficiency for ExpreS2ion Biotech Holding AB (2016–2025)
The table below shows the annual cash flow conversion efficiency of ExpreS2ion Biotech Holding AB from 2016 to 2025. Review ExpreS2ion Biotech Holding AB free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr35.69 Million ≈ $3.84 Million |
Skr-40.90 Million ≈ $-4.40 Million |
-1.146x | -117.64% |
| 2024-12-31 | Skr64.42 Million ≈ $6.93 Million |
Skr-33.93 Million ≈ $-3.65 Million |
-0.527x | +65.88% |
| 2023-12-31 | Skr65.36 Million ≈ $7.03 Million |
Skr-100.89 Million ≈ $-10.86 Million |
-1.543x | -60.10% |
| 2022-12-31 | Skr103.33 Million ≈ $11.12 Million |
Skr-99.61 Million ≈ $-10.72 Million |
-0.964x | -196.42% |
| 2021-12-31 | Skr140.35 Million ≈ $15.10 Million |
Skr-45.65 Million ≈ $-4.91 Million |
-0.325x | -69.19% |
| 2020-12-31 | Skr94.55 Million ≈ $10.17 Million |
Skr-18.18 Million ≈ $-1.96 Million |
-0.192x | -101.63% |
| 2019-12-31 | Skr-1.08 Million ≈ $-116.12K |
Skr-12.69 Million ≈ $-1.37 Million |
11.762x | +858.09% |
| 2018-12-31 | Skr8.30 Million ≈ $893.32K |
Skr-12.88 Million ≈ $-1.39 Million |
-1.551x | -21.43% |
| 2017-12-31 | Skr6.74 Million ≈ $725.01K |
Skr-8.61 Million ≈ $-926.36K |
-1.278x | -134.40% |
| 2016-12-31 | Skr12.88 Million ≈ $1.39 Million |
Skr-7.02 Million ≈ $-755.57K |
-0.545x | -- |
About ExpreS2ion Biotech Holding AB
ExpreS2ion Biotech Holding AB (publ), a clinical-stage biotechnology company, develops protein-based immunotherapies and vaccines for oncology and infectious diseases in the Nordics and internationally. The company's lead asset is ES2B-C001, an immunotherapy candidate, which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2, as well as vacci… Read more